http://hivdb.stanford.edu News and updates about Stanford HIVDB Tue, 12 Jul 2007 21:00:00 PST en-us Fri, 02 May 2008 21:00:00 PST http://hivdb.stanford.edu/pages/news/index.html#n12 A few DRV scores and comments were updated. For more details follow this link Fri, 29 Apr 2008 21:00:00 PST http://hivdb.stanford.edu/pages/news/index.html#n11 A few scores and comments were updated. For more details follow this link Mon, 12 Jul 2007 21:00:00 PST http://hivdb.stanford.edu/pages/news/index.html#n10 Scores and comments for TMC125, a new NNRTI drug, were added. For more details follow this link Tue, 30 Jan 2007 21:00:00 PST http://hivdb.stanford.edu/pages/news/index.html#n9 Antiretroviral Therapy - Acquisition and Display Engine (ART-AiDE), electronic Clinical Antiretroviral Resistance Estimator (eCARE), and Calibrated Population Resistance (CPR) were launched. For more details follow this link Mon, 04 Dec 2006 21:00:00 PST http://hivdb.stanford.edu/pages/news/index.html#n8 A few scores for PI drugs were updated. For more details follow this link Mon, 21 Nov 2006 21:00:00 PST http://hivdb.stanford.edu/pages/news/index.html#n7 A few scores for PI drugs and comments were updated, especially TPV. fAPV was renamed FPV and TMC114 was renamed DRV. For more details follow this link Mon, 11 Oct 2006 21:00:00 PST http://hivdb.stanford.edu/pages/news/index.html#n6 A few scores for PI drugs were updated, especially TMC 114. For more details follow this link Mon, 18 Sep 2006 21:00:00 PST http://hivdb.stanford.edu/pages/news/index.html#n5 Scores for ANRS resistance algorithm were updated to 2006 July version. For more details follow this link to their site Mon, 18 Sep 2006 21:00:00 PST http://hivdb.stanford.edu/pages/news/index.html#n4 Scores and comments for PI drugs were updated, especially TMC 114. For more details follow this link Tue, 22 Aug 2006 21:00:00 PST http://hivdb.stanford.edu/pages/news/index.html#n3 PI resistance summary pages have been updated to reflect recently reported data relevant to atazanavir (ATV), tipranavir (TPV), and darunavir (DRV, TMC114). Most of the changes reflect data from salvage therapy trials. Sequences from TPV and DRV treated persons have not yet been submitted to the database. TPV and DRV drug susceptibility data have also not yet been submitted to the database. Researchers who would like to submit such data should contact us at HIVDB. Tue, 30 May 2006 21:00:00 PST http://hivdb.stanford.edu/pages/news/index.html#n2 We are seeking two post-doctoral fellows to perform studies of HIV sequence variation, molecular evolution, population genetics, and antiviral drug resistance; to develop software to assist other researchers performing similar analyses; and to further the development of the Stanford HIV Drug Resistance Database (http://hivdb.stanford.edu). Candidates should have degrees in biology, biomedical informatics, or statistics and be motivated to innovate and publish. Candidates will have to become highly knowledgeable about the biological and clinical aspects of HIV drug resistance and how the data representing this knowledge is organized in the Stanford database. Candidates will need to be able to write their own programs for querying the Stanford database and for performing statistical and machine learning analyses of data within the Stanford database as well as of data from additional ongoing collaborations. Ideally, one candidate will have a stronger computer programming background and will contribute to improving the database and its tools and another will have a stronger analytic background with statistical skills and an understanding of molecular evolution and population genetics analyses. Please e-mail your CV, a brief statement, and the names, telephone numbers, and e-mail addresses of three references to HIVDB. Wed, 25 May 2005 21:00:00 PST http://hivdb.stanford.edu/pages/news/index.html#n1 Show us the data. To better meet their responsibility, the FDA should encourage pharmaceutical companies to release the data supporting the activity of new HIV drugs against drug-resistant viruses.The full text of the letter >>